Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trabectedin in HEY1-NCOA2 positive mesenchymal chondrosarcoma
2024-514319-85-00Phase 2Authorised
- Sponsor
- Italian Sarcoma Group
- Start
- Jul 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in mesenchymal chondrosarcoma (MCS), sponsored by Italian Sarcoma Group. Primary endpoint: Overall tumour Response Rate according to RECIST v1.1. Planned start Jul 2024; status: authorised.
02
Drugs
trabectedin
03
Conditions
mesenchymal chondrosarcoma (MCS)
Beyond the preview
Go deeper on 2024-514319-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514319-85-00.